212 related articles for article (PubMed ID: 36825106)
1. Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer.
Yokota T
Case Rep Oncol; 2022; 15(3):833-840. PubMed ID: 36825106
[TBL] [Abstract][Full Text] [Related]
2. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
[TBL] [Abstract][Full Text] [Related]
3. Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea.
Baek HS; Ha J; Ha S; Bae JS; Jung CK; Lim DJ
Curr Oncol; 2023 Mar; 30(3):3020-3031. PubMed ID: 36975442
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib and selpercatinib successfully treated RET fusion gene-positive papillary thyroid carcinoma cardiac metastases: a case report.
Toda S; Yamamoto Y; Ookubo Y; Hayashi H; Tsunematsu T; Kadoya M; Masudo K; Iwasaki H
Gland Surg; 2023 Oct; 12(10):1441-1448. PubMed ID: 38021198
[TBL] [Abstract][Full Text] [Related]
5. Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.
Nie T; Syed YY
Target Oncol; 2023 Jan; 18(1):169-176. PubMed ID: 36422787
[TBL] [Abstract][Full Text] [Related]
6. Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer.
Chen M; Xue J; Sang Y; Jiang W; He W; Hong S; Lv W; Xiao H; Liu R
BMC Cancer; 2023 Apr; 23(1):363. PubMed ID: 37081420
[TBL] [Abstract][Full Text] [Related]
7. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
[TBL] [Abstract][Full Text] [Related]
8. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.
Illini O; Hochmair MJ; Fabikan H; Weinlinger C; Tufman A; Swalduz A; Lamberg K; Hashemi SMS; Huemer F; Vikström A; Wermke M; Absenger G; Addeo A; Banerji S; Calles A; Clarke S; Di Maio M; Durand A; Duruisseaux M; Itchins M; Kääränien OS; Krenn F; Laack E; de Langen AJ; Mohorcic K; Pall G; Passaro A; Prager G; Rittmeyer A; Rothenstein J; Schumacher M; Wöll E; Valipour A
Ther Adv Med Oncol; 2021; 13():17588359211019675. PubMed ID: 34178121
[TBL] [Abstract][Full Text] [Related]
9. Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors.
Le D; Konda B
Expert Rev Anticancer Ther; 2023; 23(11):1117-1122. PubMed ID: 37795873
[TBL] [Abstract][Full Text] [Related]
10. Predictive molecular pathology in metastatic thyroid cancer: the role of
Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189
[TBL] [Abstract][Full Text] [Related]
11. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
12. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
[TBL] [Abstract][Full Text] [Related]
13. Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.
Belluomini L; Avancini A; Pasqualin L; Insolda J; Sposito M; Menis J; Tregnago D; Trestini I; Ferrara MG; Bria E; Milella M; Pilotto S
Expert Rev Anticancer Ther; 2022 Aug; 22(8):785-794. PubMed ID: 35726802
[TBL] [Abstract][Full Text] [Related]
14. Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer.
Chen W; Dream S; Leung PY; Wu PK; Wong S; Park JI
NPJ Precis Oncol; 2024 Feb; 8(1):39. PubMed ID: 38378752
[TBL] [Abstract][Full Text] [Related]
15. Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC.
De Carlo E; Bertoli E; Schiappacassi M; Stanzione B; Del Conte A; Doliana R; Spina M; Bearz A
Front Oncol; 2024; 14():1307458. PubMed ID: 38420011
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of selpercatinib in Chinese patients with advanced
Zheng X; Ji Q; Sun Y; Ge M; Zhang B; Cheng Y; Lei S; Shi F; Guo Y; Li L; Chen L; Shao J; Zhang W; Gao M
Ther Adv Med Oncol; 2022; 14():17588359221119318. PubMed ID: 36062046
[TBL] [Abstract][Full Text] [Related]
17. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
Acharya B; Frett B
Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171
[TBL] [Abstract][Full Text] [Related]
18. Real-world clinical profile, treatment patterns and patient-reported outcomes for thyroid cancer in Japan.
Fukuda N; Tanizawa Y; Nakamura K; Okada Y; Segall G; Kiiskinen U; Fasnacht N; Sanderson I; Rider A; Lewis K
Future Oncol; 2023 May; 19(16):1125-1137. PubMed ID: 37278236
[TBL] [Abstract][Full Text] [Related]
19. Current perspectives on the management of patients with advanced
Elisei R; Grande E; Kreissl MC; Leboulleux S; Puri T; Fasnacht N; Capdevila J
Front Oncol; 2023; 13():1141314. PubMed ID: 37207147
[TBL] [Abstract][Full Text] [Related]
20. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.
Lee YA; Lee H; Im SW; Song YS; Oh DY; Kang HJ; Won JK; Jung KC; Kwon D; Chung EJ; Hah JH; Paeng JC; Kim JH; Choi J; Kim OH; Oh JM; Ahn BC; Wirth LJ; Shin CH; Kim JI; Park YJ
J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34237031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
